Treatment of acute myelogenous leukemia with 6-MPR.
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D012263:Ribonucleosides; D011239:Prednisolone; D015122:Mercaptopurine; D000410:Alanine Transaminase